Glatiramer Acetate

Glatiramer acetate (Copaxone) is a real, FDA-approved multiple sclerosis treatment built from a synthetic mixture of four amino acids designed to mimic myelin — and its own FDA label states plainly that its mechanism of action still isn't fully understood, despite three decades on the market.

Not a single peptide — a random copolymer

Glatiramer acetate isn't a single defined peptide the way most entries on this site are. It's a synthetic random co-polymer of four amino acids — L-glutamic acid, L-alanine, L-tyrosine, and L-lysine — in a fixed molar ratio but with no single defined sequence or molecular weight, designed to structurally resemble myelin basic protein, the substance the immune system attacks in multiple sclerosis. That heterogeneity is precisely why later manufacturers couldn't simply copy it as a straightforward small-molecule generic — see below.

The approvals and pivotal trials

The FDA approved the original 20mg daily formulation of Copaxone on 20 December 1996 for relapsing-remitting MS, based on a pivotal Phase III trial (The Copolymer 1 Multiple Sclerosis Study Group, Neurology 1995, PMID 7617181): 251 patients across 11 US centers, 2 years, finding a 29% reduction in relapse rate versus placebo (1.19 vs. 1.68 relapses, p=0.007) — a real, statistically significant, but genuinely modest effect, not a cure. A three-times-weekly 40mg formulation was approved in January 2014 based on the GALA trial (Khan et al., Ann Neurol 2013, PMID 23686821; 1,404 patients, 142 sites), which found about a 34% reduction in confirmed relapse rate versus placebo at 12 months. The FDA-approved prescribing information states directly: "The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood" — real, current label language, not a simplification on our part.

The generic fight that followed

Because glatiramer acetate has no single defined structure, proving a generic version is truly equivalent was genuinely harder than for an ordinary small-molecule drug, and Teva (Copaxone's maker) fought to keep it that way through patent litigation and multiple FDA citizen petitions. Sandoz, in partnership with Momenta Pharmaceuticals, eventually won FDA approval for Glatopa (a generic 20mg daily version) on 16 April 2015, the same day a Federal Circuit ruling invalidated Teva's last relevant patent — the first real generic competition Copaxone faced since 1996.

Current status

Multiple generics of the 20mg daily formulation have been available since 2015; branded Copaxone reportedly still holds roughly half of Medicare Part D glatiramer prescriptions despite that competition (a single-source figure — treat as approximate). No grey-market or wellness angle applies to this drug at all; it's prescribed exclusively for diagnosed MS.